Stifel Financial Corp Reduces Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

Stifel Financial Corp reduced its holdings in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 25.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,807 shares of the company's stock after selling 4,366 shares during the period. Stifel Financial Corp's holdings in BeiGene were worth $2,875,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BGNE. Blue Trust Inc. grew its holdings in BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock valued at $28,000 after buying an additional 75 shares in the last quarter. Raymond James & Associates boosted its position in shares of BeiGene by 0.4% during the 2nd quarter. Raymond James & Associates now owns 21,275 shares of the company's stock valued at $3,035,000 after acquiring an additional 76 shares during the last quarter. Truist Financial Corp grew its holdings in shares of BeiGene by 10.1% in the second quarter. Truist Financial Corp now owns 1,521 shares of the company's stock valued at $217,000 after purchasing an additional 140 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in BeiGene during the third quarter worth about $36,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in BeiGene by 0.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company's stock worth $21,978,000 after purchasing an additional 266 shares during the period. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeiGene Stock Down 1.8 %

Shares of NASDAQ:BGNE traded down $3.19 during trading on Wednesday, hitting $175.87. The company's stock had a trading volume of 592,186 shares, compared to its average volume of 284,504. The company has a market capitalization of $17.14 billion, a PE ratio of -21.34 and a beta of 0.57. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $248.16. The business has a 50 day moving average price of $204.77 and a two-hundred day moving average price of $187.51.

BeiGene (NASDAQ:BGNE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene's revenue for the quarter was up 28.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 EPS. As a group, research analysts expect that BeiGene, Ltd. will post -5.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BGNE. Morgan Stanley restated an "overweight" rating and set a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. TD Cowen increased their target price on shares of BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. JMP Securities assumed coverage on shares of BeiGene in a research note on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price target on the stock. StockNews.com cut shares of BeiGene from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, JPMorgan Chase & Co. boosted their target price on BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research report on Tuesday, October 22nd. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, BeiGene presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.69.

Insider Activity at BeiGene

In related news, COO Xiaobin Wu sold 4,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $200.14, for a total value of $900,630.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John Oyler sold 6,175 shares of the firm's stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. Insiders have sold a total of 1,136,122 shares of company stock valued at $213,421,417 over the last 90 days. 7.43% of the stock is owned by corporate insiders.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.